All canine diagnoses

Your dog was diagnosed with Nasal Carcinoma (Adenocarcinoma / SCC). ~1-2% of all canine tumours. Most common nasal tumour type. Adenocarcinoma most frequent histotype. Locally invasive; distant metastasis late in disease. Dolichocephalic and mesocephalic breeds overrepresented. Compare 3 treatment options for dogs including Definitive Radiation Therapy, Palliative Radiation (Coarse Fractionation), NSAID Therapy + Supportive Care (Palliation) — with survival times, costs, and what to expect during treatment.

🐕

Nasal Carcinoma (Adenocarcinoma / SCC)

Modified Adams staging (I-IV)

BreedsAiredale TerrierOld English SheepdogScottish TerrierCollieShetland SheepdogGerman ShepherdGolden RetrieverLabrador Retriever
canine

Epithelial

About This Cancer

Nasal carcinomas are cancers arising from the epithelial lining of the nasal cavity and paranasal sinuses. Adenocarcinoma is the most common type, followed by squamous cell carcinoma. These tumours are locally invasive, progressively destroying the delicate bone and tissue structures within the nose, and typically present with signs such as nasal discharge (often bloody), sneezing, noisy breathing, or facial deformity as the tumour expands. One important characteristic of nasal carcinomas is that while they are very destructive locally, they tend to spread to distant sites (metastasise) late in the disease course. This means that local control — particularly with radiation therapy — can provide meaningful survival benefit. A critical prognostic factor is whether the tumour has eroded through the cribriform plate (the bone separating the nasal cavity from the brain), as this significantly worsens the outlook.

Modified Adams Staging for Canine Nasal Tumours

Based on CT extent of tumour invasion

Stage ITumour confined to one nasal passage, paranasal sinus, or nasal fossa, with no bone involvement
Stage IIBone involvement (turbinate lysis, vomer, septum) but confined to nasal cavity
Stage IIITumour extends to orbit or subcutaneous tissues, or through cribriform plate
Stage IVTumour extends into nasopharynx or cribriform plate with CNS involvement
Prognostic Factors(3)
Cribriform plate involvementExtension through cribriform plate significantly worsens prognosis. Associated with CNS invasion.(Adams et al., 2009)
Histological typeCarcinomas (adenocarcinoma, SCC) respond better to radiation than sarcomas. Undifferentiated tumours intermediate.
Tumour stageStage I-II respond better to radiation than Stage III-IV.
Minimum Workup(6 steps)
1CT scan of skull (essential for staging and radiation planning — superior to radiographs)
2Rhinoscopy with biopsy (histological diagnosis essential)
3Thoracic radiographs (3-view) for pulmonary metastasis screening
4Regional lymph node assessment (retropharyngeal, mandibular)
5Complete blood count and serum biochemistry
6Coagulation panel (nasal tumours may cause epistaxis)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Definitive Radiation Therapy
~18 mo (12–30)
Palliative Radiation (Coarse Fractionation)
~7 mo (4–12)
NSAID Therapy + Supportive Care (Palliation)
~5 mo (2–8)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.